RightFit
RecruitingPhase not listed

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: MRI scans, PET scans, Blood draws, Physical exams

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "The study will use structural and functional MRIs, daTscans, fluorodeoxyglucose (FDG) PET scans, Amyvid PET scans, polysomnographs, neuropsychological testing, cerebrospinal fluid in willing participants to distinguish between a diagnosis of Alzheimer's disease, Lewy Body dementia, and Parkinson's Disease."
  • "All subjects will have a clinical evaluation, physical examination including vital signs and orthostatic blood pressures and pulses, neurological examination including UPDRS evaluation, genetic blood sample collection, neuropsychological testing, polysomnogram, and neuroimaging."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study compares symptoms, thinking and memory, sleep test results, and brain images. It is for people with Alzheimer's disease, Lewy body dementia, or Parkinson's disease.

The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Meet the standard medical rules for a diagnosis of one of the three diseases.
  • Have enough thinking skills to finish study tasks, with a score of at least 10 on the Mini Mental State Examination (MMSE).
  • Have no changes to medicines for thinking, mood, or behavior in the 4 weeks before joining.
  • Have a responsible study partner who lives with you or has regular contact with you at least 4 days a week.
  • Be able to see and hear well enough to do the tests.

Who can't join

  • Have another condition that study doctors think may add to dementia symptoms or make them harder to assess.
  • Have a current medical problem that could prevent you from taking part.
  • Are pregnant or breastfeeding.
  • Have severe kidney problems, with a kidney filtering rate (GFR) below 30.
  • Do not have English as your first language.
  • Have fewer than 12 years of schooling.
  • Have ever joined a study of an experimental treatment targeting amyloid, a protein, unless records show you received only a placebo (a treatment with no active drug).

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Subjects must meet the standard clinical criteria of the syndromes of interest * All subjects must have enough cognitive abilities to complete study procedures, which will be operationally defined as having a Mini Mental State Examination (MMSE) score greater or equal to 10. * Subjects must be on stable cognitive and psychoactive medication regimen for the preceding four weeks of enrollment. * Subjects must have a responsible study partner that either lives with them or is in regular contact with them at least 4 out of 7 days per week. * Subjects must have visual and auditory acuity adequate for testing. Exclusion Criteria: * Any other condition (other than the primary diagnosis), which in the opinion of the investigators might contribute to the syndrome of dementia or complicate its assessment. * active medical disorder that could preclude participation in this protocol * Women who are pregnant or are breast feeding * severe renal impairment as defined by glomerular filtration rate (GFR) less than 30 (may have increased radiation exposure with the DaTscan). * Subjects in whom English is not the 1st language * Subjects with educational level less than 12 years * Subjects who have ever participated in an experimental study with an amyloid targeting agent unless it can be documented that the subject received only placebo during the course of the trial.

Study sites (1)

OH